Erratum: Novel approaches to inhibition of gastric acid secretion (Current Gastroenterology Reports DOI: 10.1007/s11894-010-0149-5);Novel approaches to inhibition of gastric acid secretion

Current Gastroenterology Reports

Volumn 12, Issue 6, 2010, Pages 437-447

  Sachs, George ^a   Shin, Jai Moo ^a   Hunt, Richard ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Gastric H,K ATPase; Gastroesophageal reflux disease; Proton pump inhibitor; Ulcer

Indexed keywords

8 (2,6 DIMETHYLBENZYLAMINO) N (2 HYDROXYETHYL) 2,3 DIMETHYLIMIDAZO[1,2 A]PYRIDINE 6 CARBOXAMIDE; 8 BENZYLOXY 2 METHYLIMIDAZO[1,2 A]PYRIDINE 3 ACETONITRILE; AGN 201904 Z; ALEVIUM; AMOXICILLIN; ANTIBIOTIC AGENT; BENATOPRAZOLE; CIMETIDINE; CLARITHROMYCIN; DEXLANSOPRAZOLE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; POTASSIUM COMPETITIVE ACID BLOCKER; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SORAPRAZAN; TAK 438; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DUODENUM ULCER; ERADICATION THERAPY; EVENING DOSAGE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MORNING DOSAGE; NON EROSIVE REFLUX DISEASE; NONHUMAN; PEPTIC ULCER; PHARMACODYNAMICS; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID SECRETION; STOMACH ULCER; ULCER HEALING;

EID: 78649908709     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-010-0159-3     Document Type: Erratum

References (38)

1. N Chiba CJ De Gara JM Wilkinson RH Hunt 1997 Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis Gastroenterology 112 1798 1810 1:STN:280:DyaK2szit1Sitw%3D%3D 10.1053/gast.1997.v112.pm9178669 9178669 (Pubitemid 27240763)
2. S Teyssen ST Chari J Scheid MV Singer 1995 Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects Dig Dis Sci 40 247 255 1:CAS:528:DyaK2MXltlGrtL0%3D 10.1007/BF02065405 7851185
3. K Gedda D Scott M Besancon, et al. 1995 Turnover of the gastric H+, K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion Gastroenterology 109 1134 1141 1:CAS:528: DyaK2MXos1aqtb8%3D 10.1016/0016-5085(95)90571-5 7557078
4. R Fass M Shapiro R Dekel J Sewell 2005 Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 22 79 94 1:CAS:528:DC%2BD2MXpt1Cjt70%3D 10.1111/j.1365-2036.2005. 02531.x 16011666
5. WD Chey JM Inadomi AM Booher, et al. 2005 Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey Am J Gastroenterol 100 1237 1242 10.1111/j.1572-0241.2005.41364.x 15929751 (Pubitemid 40904343)
6. J Pezanoski N Guanaratnam M Cowen 2003 Correct and incorrect dosing of proton pump inhibitors and its impact on GERD symptoms Gastroenterology 124 Suppl 1 A228 10.1016/S0016-5085(03)81145-9
7. RH Hunt 2005 Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005 Aliment Pharmacol Ther 22 Suppl 3 10 19 1:CAS:528:DC%2BD28Xkt1CmsQ%3D%3D 10.1111/j.1365-2036.2005.02715.x 16303032
8. Scarpignato C, Hunt RH: Non-steroidal anti-inflammatory drug related injury of the gastrointestinal tract: clinical picture pathogenesis and prevention. Gastroenterol Clin North Am 2010, in press.
9. • Raghunath AS, Hungin AP, Mason J, Jackson W: Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors. Aliment Pharmacol Ther 2009, 29:431-439. Patients often suffer ongoing moderate or severe symptoms when on long-term treatment. GERD and uninvestigated dyspepsia were associated with poor long-term symptom control.
10. Yuan Y, Wang CC, Yuan Y, Hunt RH: The proportion of patients who are free of reflux symptoms during the initial days of treatment with proton pump inhibitors (PPIs) in GERD trials: a meta-analysis. Gastroenterology 2008; 134(4, Suppl 1):A174. Abstract S1085.
11. Y Yuan B Vinh 2009 Hunt RH: Nonhealed rate of moderate-severe (LA Classification Grade C and D) erosive esophagitis after 4-8 weeks proton pump inhibitors (PPIs): evidence of an unmet need Gastroenterology 136 Suppl A440
12. RH Hunt 1999 Importance of pH control in the management of GERD Arch Intern Med 159 649 657 1:STN:280:DyaK1M3jtlWisw%3D%3D 10.1001/archinte.159.7.649 10218743 (Pubitemid 29177653)
13. Y Yuan 2009 Hunt RH: Intragastric pH holding time pH∈<∈3 at steady state in healthy volunteers (HV) after once daily PPIs: a predictor for low erosive esophagitis (EE) healing rates? Gastroenterology 136 Suppl M1990
14. CC Wang Y Yuan Y Chen RH Hunt 2008 Night-time pH holding time: what is hidden by the% of time pH∈≥∈4? Am J Gastroenterol 103 Suppl 1 S51
15. G Karamanolis T Vanuytsel D Sifrim, et al. 2008 Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy Dig Dis Sci 53 2387 2393 10.1007/s10620-007-0186-6 18322797
16. Y Yuan 2008 Hunt RH: Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? Am J Gastroenterol 103 Suppl S50
17. WC Orr 2006 Reflux events and sleep: are we vulnerable? Curr Gastroenterol Rep 8 202 207 10.1007/s11894-006-0076-7 16764786
18. JE Richter 2006 The patient with refractory gastroesophageal reflux disease Dis Esophagus 19 443 447 1:STN:280:DC%2BD28njsVWruw%3D%3D 10.1111/j.1442-2050.2006.00619.x 17069586 (Pubitemid 44644679)
19. JE Richter 2007 How to manage refractory GERD Nat Clin Pract Gastroenterol Hepatol 4 658 664 10.1038/ncpgasthep0979 18043675 (Pubitemid 350193815)
20. PO Katz DO Castell Y Chen, et al. 2004 Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study Aliment Pharmacol Ther 20 399 406 1:CAS:528:DC%2BD2cXnvVyjtrs%3D 10.1111/j.1365-2036.2004.02079.x 15298633 (Pubitemid 39120250)
21. WD Chey R Mody L Chen, et al. 2008 Nighttime symptoms and sleep impairment among patients with gastro-esophageal reflux disease (GERD) receiving prescription (Rx) proton pump inhibitors (PPIs) Gastroenterology 134 4 Suppl 1 A323 A324
22. R Shaker DO Castell PS Schoenfeld SJ Spechler 2003 Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association Am J Gastroenterol: 98 1487 1493 10.1111/j.1572-0241.2003.07531.x
23. • Yuan Y, Hunt RH Evolving issues in the management of reflux disease? Curr Opin Gastroenterol 2009, 25:342-351. Although GERD is common, management still poses many challenges, which are addressed in this paper together with the unmet needs in reflux disease.
24. JM Shin YM Cho G Sachs 2004 Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors J Am Chem Soc 126 7800 7811 1:CAS:528:DC%2BD2cXksFelt7g%3D 10.1021/ja049607w 15212527 (Pubitemid 38812770)
25. JM Shin M Homerin F Domagala H Ficheux G Sachs 2006 Characterization of the inhibitory activity of tenatoprazole on the gastric H+, K∈+∈- ATPase in vitro and in vivo Biochem Pharmacol 71 837 849 1:CAS:528: DC%2BD28XhtlKmtLg%3D 10.1016/j.bcp.2005.11.030 16405921 (Pubitemid 43208840)
26. JM Shin G Sachs 2004 Differences in binding properties of two proton pump inhibitors on the gastric H+, K∈+∈-ATPase in vivo Biochem Pharmacol 68 2117 2127 1:CAS:528:DC%2BD2cXovV2hurk%3D 10.1016/j.bcp.2004.07.035 15498502 (Pubitemid 39446139)
27. JP Galmiche 2004 Bruley Des Varannes S, Ducrotté P, et al.: Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers Aliment Pharmacol Ther 19 655 662 1:CAS:528:DC%2BD2cXjslyhurg%3D 10.1111/j.1365-2036.2004.01893.x 15023167 (Pubitemid 38445426)
28. JP Galmiche S Sacher-Huvelin 2005 Bruley des Varannes S, et al.: A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers Aliment Pharmacol Ther 21 575 582 1:CAS:528:DC%2BD2MXjt12ksrs%3D 10.1111/j.1365-2036.2005.02381.x 15740541 (Pubitemid 40381509)
29. M Vakily W Zhang J Wu, et al. 2009 Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials Curr Med Res Opin 25 627 638 1:CAS:528:DC%2BD1MXltVWmsbc%3D 10.1185/03007990802693883 19232037
30. • Sharma P, Shaheen NJ, Perez MC, et al.: Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment Pharmacol Ther 2009, 29:731-741. This study showed that dexlansoprazole MR is highly effective in healing erosive esophagitis and offers benefits over lansoprazole, particularly in moderate-to-severe disease.
31. CW Howden LM Larsen MC Perez, et al. 2009 Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis- maintenance of healing and symptom relief Aliment Pharmacol Ther 30 895 907 1:CAS:528:DC%2BD1MXhtl2kurrE 10.1111/j.1365-2036.2009.04119.x 19681809
32. • Hunt RH, Armstrong D, Yaghoobi M, et al.: Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008, 28:187-199. This study showed that a PPI prodrug, AGN201904-Z, provided superior acid control over esoemprazole. Longer duration of the effective plasma concentration of drug was achieved by slow absorption of the prodrug.
33. C Nilsson E Albrektson H Rydholm, et al. 2005 Tolerability, pharmacokinetics and effects on gastric acid secretion after single oral doses of the potassium-competitive acid blocker AZD0865 in healthy male subjects Gastroenterology 128 4 Suppl 2 A528
34. • Dent J, Kahrilas PJ, Hatlebakk J, et al.: A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008, 103:20-26. This article provides a comparison of a short acting K-competitive inhibitor of the H,K-ATPase with a PPI.
35. PJ Kahrilas J Dent K Lauritsen, et al. 2007 A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis Clin Gastroenterol Hepatol 5 1385 1391 1:CAS:528: DC%2BD1cXlslSrtQ%3D%3D 10.1016/j.cgh.2007.08.014 17950677 (Pubitemid 350181597)
36. WA Simon M Herrmann T Klein, et al. 2007 Soraprazan: setting new standards in inhibition of gastric acid secretion J Pharmacol Exp Ther 321 866 874 1:CAS:528:DC%2BD2sXmsFGntLw%3D 10.1124/jpet.107.120428 17369284 (Pubitemid 46762698)
37. Kajino M, Nishida H, Arikawa Y, Hirase K, Ono K, inventors; Takeda Pharmaceutical Company, assignee. Pyrrole compounds. Japanese patent WO 2008/108380 A2. September 12, 2008.
38. Hori Y, Imanishi A, Matsukawa J, et al.: 1-[5-(2-Fluorophenyl)-1- (pyridin-3-ylsulfonyl)-1 H-pyrrol-3-yl]-N-methylmet hanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010 (Epub ahead of print).